Sun Pharmaceutical Industries Ltd was founded in the year 1983 by Dilip Shanghvi, with only five psychiatry products and a two-person marketing team. It is an Indian multinational pharmaceutical company headquartered in Goregaon, Mumbai, Maharashtra. The company holds total Revenue of 30,091.4 crores INR and more than 32,000 employees as per 2019 statistics. The firm is a huge name in the field of medicine manufactures and sells active pharmaceutical ingredients and pharmaceutical formulations primarily in India and the USA. Sun Pharma Industries also has many Subsidiaries, Ranbaxy Laboratories, Chattem Chemicals, Inc, Sun Petrochemicals Private Limited, Alkaloida Chemical Company Zrt, Sun Ophthalmics Inc., Sun Pharma Global FZE and others.

The company supplies Active Pharmaceutical Ingredients such as clorazepate, warfarin, etodolac, and carbamazepine to other manufacturers. The firm also sells anti-cancers, controlled substances, steroids, sex hormones, and peptides. Sun Pharma provides products in many therapeutic areas, including diabetology, cardiology, gastroenterology, psychiatry and neurology. Today Sun Pharma has more than 40 manufacturing sites across 100 markets and sells around 2000 marketed products. 

Sun Pharma establishes the first research centre in 1991, to create a base for the strong product and process development. In the year 1996, Sun Pharma purchased an MJ Pharma's dosage plant at Halol and bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals and got both of them approved by U.S. FDA. In the year 1987 Sun Pharma began the selling of products across the nation. The company also acquired a number of respiratory brands from Natco Pharma in the year 1998. In 2010, Sun Pharma acquired a large stake in Taro Pharmaceuticals. This was amongst the largest generic derma care companies in the US, with operations across Canada and Israel. In 2013, Ranbaxy acquisition catapults Sun Pharma to world’s 5th largest speciality generic pharmaceutical company.